
Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

